Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03057756
Other study ID # TB-MR 001/2015
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 11, 2015
Est. completion date July 1, 2023

Study information

Verified date July 2021
Source Centre de Recherche Médicale de Lambaréné
Contact Ayola A Adegnika, MD, PhD
Phone +24107406464
Email aadegnika@cermel.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.


Description:

Study participants will be followed up, under existing protocol derived from a study protocol developed by the "Union internationale contre les maladies respiratoires" and carried out already in 9 Africans countries. Participants will be hospitalised for at least four month, period which they will be given treatments, assessed for adverse events, monitored for TB-MR strains using culture techniques, at the monthly basis. If patients found with negative sputum culture at month four they will be dischrged from the hospital, and then treated four an additional five montns and then follow up, clinically and biologically for an additional six months before being declared as cured.


Recruitment information / eligibility

Status Recruiting
Enrollment 23
Est. completion date July 1, 2023
Est. primary completion date April 4, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years and older
Eligibility Inclusion criteria: - Aged 15 years and above - Never been treated with second line anti-TB drugs for more than one month, - Give written consent to participate - Agree to be hospitalised for at least four months in specialised healthcare - Willing to adhere to ambulatory directly observed treatment by a healthcare worker; Exclusion criteria: - Pregnant during inclusion process - Presented with altered clinical status condition as judged by the clinician - Knowing of history of hypersensitivity reaction to any of the drugs to be used - Baseline ECG does not show a QT space superior to 500ms - Refusal to participate into study.

Study Design


Related Conditions & MeSH terms

  • Multi-drug Resistant Tuberculosis
  • Tuberculosis
  • Tuberculosis, Multidrug-Resistant

Intervention

Combination Product:
Km+ Mfx+ Pto + H + Cfz +E+Z
Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide

Locations

Country Name City State
Gabon Centre de Recherches Médicales de Lambaréné Lambarene Please Select

Sponsors (3)

Lead Sponsor Collaborator
Centre de Recherche Médicale de Lambaréné Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Institute of Tropical Medicine, University of Tuebingen

Country where clinical trial is conducted

Gabon, 

References & Publications (8)

Chiang CY, Caminero JA, Enarson DA. Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome 'failed'. Int J Tuberc Lung Dis. 2009 May;13(5):548-50. Review. — View Citation

Eurosurveillance editorial team. WHO revised definitions and reporting framework for tuberculosis. Euro Surveill. 2013 Apr 18;18(16):20455. — View Citation

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev — View Citation

Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcón E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. I — View Citation

Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union a — View Citation

Stolp SM, Huson MA, Janssen S, Beyeme JO, Grobusch MP. Tuberculosis patients hospitalized in the Albert Schweitzer Hospital, Lambaréné, Gabon-a retrospective observational study. Clin Microbiol Infect. 2013 Nov;19(11):E499-501. doi: 10.1111/1469-0691.1227 — View Citation

Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92. doi: 10.1164/rccm.201001-0077OC. — View Citation

World Health Organization; International Union Against Tuberculosis and Lung Disease; Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis. 2001 Mar;5(3):213-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary cure rate post treatment Proportion of participants alive and presented with negative sputum culture for TB and with the absence of clinical, X-Ray and biological disorders related to TB Six months post treatment
Secondary TB-culture First TB culture negative time 4 months after start of the treatment
Secondary Regimen tolorability treatment, safety through clinical and biological assessment Throughout treatment period (9months)
Secondary Adverse events solicited and unsolicited adverse events duration of participant in the study (15months)
See also
  Status Clinical Trial Phase
Completed NCT04207112 - Economic Evaluation of New MDR TB Regimens Phase 2/Phase 3
Completed NCT03000517 - PK of Levofloxacin in MDR-TB Patients N/A
Completed NCT03470233 - Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB
Completed NCT03830671 - The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB Phase 4
Withdrawn NCT01600963 - A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis Phase 3
Recruiting NCT03575299 - Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells Phase 1
Recruiting NCT03827811 - Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
Completed NCT04342598 - Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
Completed NCT04309656 - A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid Phase 1
Completed NCT03822156 - Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort
Completed NCT00425113 - Metronidazole for Pulmonary Tuberculosis (South Korea) Phase 2
Active, not recruiting NCT04081077 - PRACTECAL-PKPD Sub Study Phase 2/Phase 3
Recruiting NCT04397536 - New Genomic Techniques and Management of Multidrug-resistant Tuberculosis
Completed NCT00691392 - Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB) Phase 1/Phase 2
Completed NCT00664313 - TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB Phase 1/Phase 2

External Links